Feature: Peering Into My Genome
By Jennifer Couzin-Frankel,
Science
| 12. 04. 2014
Rarely could I be described in a headline in The New York Times, which explains why I lingered over one earlier this fall. “Study of Jewish Women Shows Link to Cancer Without Family History,” announced the 5 September story. Uneasily, I read on: “Women of Ashkenazi Jewish descent who tested positive for cancer-causing genetic mutations during random screenings have high rates of breast and ovarian cancer even when they have no family history of the disease, researchers reported Thursday.”
Hmmm.
Science has been my professional home for the past 13 years, and in that time I’ve written extensively about genetic testing and spoken with dozens of experts at the field’s cutting edge. I’ve chronicled the scientific advances, the ethical quandaries, the lives testing saves, the angst it ignites. I had never turned the lens on my own DNA.
Abruptly, there was no escaping it. My parents are both of Ashkenazi descent. To my knowledge, no one on either side of my family has ever had breast or ovarian cancer. But suddenly I saw how a mutation in the genes...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...